- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Hikma Pharmaceuticals PLC (HIK)
1,532.50
-32.50(-2.08%)
- Volume:562,610
- Bid/Ask:1,500.00/2,950.00
- Day's Range:1,532.50 - 1,573.00
HIK Overview
- Prev. Close
- 1,565
- Day's Range
- 1,532.5-1,573
- Revenue
- 2.55B
- Open
- 1,568
- 52 wk Range
- 1,459.5-2,625
- EPS
- 1.51
- Volume
- 562,610
- Market Cap
- 3.37B
- Dividend (Yield)
- 0.55(2.96%)
- Average Volume (3m)
- 729,479
- P/E Ratio
- -
- Beta
- 0.09
- 1-Year Change
- -37.8%
- Shares Outstanding
- 220,125,216
- Next Earnings Date
- 22 Feb 2023
What is your sentiment on Hikma Pharma?
or
Market is currently closed. Voting is open during market hours.
Hikma Pharmaceuticals PLC News
- The week ahead: Pearson, BP Plc, Taylor Wimpey, Next and WPP
- ByProactive Investors-
Monday: Pearson could surprisePearson PLC (LSE:LON:PSON) (Pearson PLC (LSE:PSON)), the London-listed educational publishing house with a market cap of more than £5.5bn, is...
- U.K. shares higher at close of trade; Investing.com United Kingdom 100 up 2.77%
- ByInvesting.com-
Investing.com – U.K. equities were higher at the close on Friday, as gains in the Industrial Transportation, Life Insurance/Assurance and Industrial Engineering sectors propelled...
Hikma Pharmaceuticals PLC Analysis
- After AstraZeneca, Oxford Nanopore Might Be The Next UK COVID Winner
Vaccines manufactured by three groups have so far been approved in the UK. They include:AstraZeneca (LON:AZN) (NASDAQ:AZN)/ Oxford University;BioNTech (NASDAQ:BNTX) / Pfizer...
- Why Remdesivir Contract Manufacturer Hikma Deserves Attention Now
Recent positive news about a COVID-19 vaccine has put the limelight on health-care and pharmaceutical companies, especially BioNTtech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA) and...
- FTSE 100 Shrugs Off UK Restrictions, Carvana Accelerates, Dollar Rallies
Equities are showing decent gains as we approach the end of the trading session.EuropeThere was some indecision in the first few hours of trading as stocks got off to a strong...
Hikma Pharmaceuticals PLC Company Profile
Hikma Pharmaceuticals PLC Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates through three segments, such as Injectables, Generics and Branded. The Injectables business develops and manufactures generic injectable products, which are primarily used in hospitals. The Generics business develops and manufactures oral and other non-injectable generic products. The Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in Middle East/North Africa (MENA). The Company’s products are sold in the retail and hospital markets. It also markets its products in Canada, which includes approximately 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products.
Read More
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 281.20 | 282.20 | 270.40 | +10.40 | +3.84% | 631.41K | London | |||
| 241.00 | 245.50 | 237.50 | +2.50 | +1.05% | 844.20K | London | |||
| 171.60 | 172.92 | 169.32 | +2.62 | +1.55% | 50.76M | London | |||
| 27.00 | 29.80 | 26.90 | -0.10 | -0.37% | 6.42M | London | |||
| 430.55 | 435.90 | 427.75 | +3.00 | +0.70% | 28.57M | London | |||
| 1,848.00 | 1,848.00 | 1,848.00 | 0.0 | 0.00% | 0.00 | London | |||
| 12.85 | 12.85 | 12.85 | +0.1000 | +0.78% | 1.82M | London | |||
| 6,404.00 | 6,466.00 | 6,332.00 | -16.0 | -0.25% | 234.49K | London | |||
| 175.60 | 176.15 | 171.95 | +2.75 | +1.59% | 4.28M | London | |||
| 191.50 | 191.50 | 191.50 | 0.00 | 0.00% | 0.00 | London | |||
| 240.00 | 247.50 | 235.10 | -8.40 | -3.38% | 2.04M | London | |||
| 121.58 | 122.02 | 120.48 | +0.36 | +0.30% | 24.58M | London | |||
| 39.00 | 39.00 | 39.00 | 0.000 | 0.00% | 165.35K | London | |||
| 2,080.00 | 2,094.00 | 2,060.00 | -4.0 | -0.19% | 138.43K | London | |||
| 0.98 | 0.98 | 0.98 | -0.00 | 0.00% | 2.00M | Aquis Exchange |
- 09 Oct 2020, 14:54Touch 27 today
- 12 Sept 2020, 12:06Next results will be super. Wait for it to hit £32 before end of this year
- 17 Jun 2020, 13:58Aim listed Dark Matter Ltd, has more potential
- 11 May 2020, 15:01This will go up & up
- 04 Dec 2019, 09:30Not as stated here (March 11)
- 04 Dec 2019, 09:29Hikma will announce their results for the year ended 31 December 2019 on 27 February 2020
- 27 Jun 2018, 09:52Any hint of progress on Advair will send this stock much higher still !
- 18 May 2018, 19:48Underpriced without the Advair approvals ' unfortunate about the 2019 target for Advair !!!
- 08 May 2018, 09:33Almost got me money back !!!